Troy  Wichterman net worth and biography

Troy Wichterman Biography and Net Worth

Troy Wichterman has been Chief Financial Officer since November 2021. Before his appointment as
Chief Financial Officer, Mr. Wichterman served as Vice President, Finance since November 2019. In that
role, Mr. Wichterman oversaw the finance and accounting organization in the areas of integrating
acquired businesses, acquisition due diligence and deal structure, SEC reporting, financial planning and
analysis, operational finance, and audit compliance. Mr. Wichterman also served as Director of Financial
Planning and Analysis from June 2016 to November 2019 and Financial Analyst from February 2015 to
June 2016. Prior to joining the company, he was most recently a Senior Financial Analyst, Acquisitions at
Ventas, a public healthcare REIT, from January 2013 to September 2014. Prior to Ventas, he was most
recently a Senior Portfolio Analyst at Heitman, a private equity REIT, from June 2009 – January 2013 and
began his career as an Auditing Associate at PwC in Chicago from 2008 to 2009. Mr. Wichterman is a
CPA (inactive) and holds a Bachelor of Business Administration degree and a Master of Accountancy
degree from the University of Wisconsin – Madison.

What is Troy Wichterman's net worth?

The estimated net worth of Troy Wichterman is at least $2.14 million as of April 18th, 2024. Mr. Wichterman owns 126,658 shares of BioLife Solutions stock worth more than $2,135,454 as of April 26th. This net worth estimate does not reflect any other investments that Mr. Wichterman may own. Additionally, Mr. Wichterman receives an annual salary of $485,200.00 as CFO at BioLife Solutions. Learn More about Troy Wichterman's net worth.

How old is Troy Wichterman?

Mr. Wichterman is currently 39 years old. There are 7 older executives and no younger executives at BioLife Solutions. The oldest executive at BioLife Solutions is Mr. Roderick de Greef, CEO & Chairman, who is 64 years old. Learn More on Troy Wichterman's age.

What is Troy Wichterman's salary?

As the CFO of BioLife Solutions, Inc., Mr. Wichterman earns $485,200.00 per year. There are 2 executives that earn more than Mr. Wichterman. The highest earning executive at BioLife Solutions is Mr. Roderick de Greef, CEO & Chairman, who commands a salary of $1,630,000.00 per year. Learn More on Troy Wichterman's salary.

How do I contact Troy Wichterman?

The corporate mailing address for Mr. Wichterman and other BioLife Solutions executives is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. BioLife Solutions can also be reached via phone at (425) 402-1400 and via email at [email protected]. Learn More on Troy Wichterman's contact information.

Has Troy Wichterman been buying or selling shares of BioLife Solutions?

During the last quarter, Troy Wichterman has sold $14,636.36 in shares of BioLife Solutions stock. Most recently, Troy Wichterman sold 956 shares of the business's stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $15.31, for a transaction totalling $14,636.36. Following the completion of the sale, the chief financial officer now directly owns 126,658 shares of the company's stock, valued at $1,939,133.98. Learn More on Troy Wichterman's trading history.

Who are BioLife Solutions' active insiders?

BioLife Solutions' insider roster includes Sarah Aebersold (VP), Todd Berard (CMO), Roderick de Greef (CFO), Karen Foster (Insider), Andrew Hinson (Director), Aby Mathew (VP), Michael Rice (CEO), Joseph Schick (Director), Marcus Schulz (CRO), and Troy Wichterman (CFO). Learn More on BioLife Solutions' active insiders.

Are insiders buying or selling shares of BioLife Solutions?

In the last twelve months, BioLife Solutions insiders bought shares 5 times. They purchased a total of 1,055,603 shares worth more than $12,648,274.13. In the last twelve months, insiders at the medical equipment provider sold shares 88 times. They sold a total of 203,083 shares worth more than $3,138,630.18. The most recent insider tranaction occured on April, 22nd when insider Sarah Aebersold sold 410 shares worth more than $6,765.00. Insiders at BioLife Solutions own 2.7% of the company. Learn More about insider trades at BioLife Solutions.

Information on this page was last updated on 4/22/2024.

Troy Wichterman Insider Trading History at BioLife Solutions

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/18/2024Sell956$15.31$14,636.36126,658View SEC Filing Icon  
3/21/2024Sell520$17.83$9,271.60127,614View SEC Filing Icon  
3/11/2024Sell361$17.42$6,288.62135,383View SEC Filing Icon  
2/21/2024Sell97$17.35$1,682.9564,823View SEC Filing Icon  
1/19/2024Sell2,419$16.76$40,542.4464,920View SEC Filing Icon  
12/22/2023Sell314$16.79$5,272.0667,339View SEC Filing Icon  
12/1/2023Sell666$12.37$8,238.4267,112View SEC Filing Icon  
11/13/2023Sell97$10.66$1,034.0267,480View SEC Filing Icon  
9/21/2023Sell539$12.70$6,845.3066,300View SEC Filing Icon  
8/25/2023Sell585$10.99$6,429.1565,933View SEC Filing Icon  
8/14/2023Sell94$12.57$1,181.5866,518View SEC Filing Icon  
6/22/2023Sell541$23.41$12,664.8166,612View SEC Filing Icon  
5/31/2023Sell560$23.21$12,997.6067,153View SEC Filing Icon  
5/16/2023Sell137$19.41$2,659.1767,713View SEC Filing Icon  
3/22/2023Sell310$21.84$6,770.4067,850View SEC Filing Icon  
3/20/2023Sell10,000$20.64$206,400.0068,160View SEC Filing Icon  
3/7/2023Sell31$22.95$711.4577,222View SEC Filing Icon  
3/1/2023Sell1,576$22.75$35,854.0077,253View SEC Filing Icon  
2/21/2023Sell117$21.47$2,511.9978,829View SEC Filing Icon  
12/22/2022Sell528$17.55$9,266.4044,651View SEC Filing Icon  
11/29/2022Sell52$19.93$1,036.3645,179View SEC Filing Icon  
11/22/2022Sell121$20.20$2,444.2045,231View SEC Filing Icon  
9/23/2022Sell569$21.91$12,466.7945,352View SEC Filing Icon  
8/16/2022Sell116$24.81$2,877.9645,972View SEC Filing Icon  
6/24/2022Sell456$15.95$7,273.2044,799View SEC Filing Icon  
5/27/2022Sell43$14.53$624.7944,418View SEC Filing Icon  
5/13/2022Sell125$12.32$1,540.0044,013View SEC Filing Icon  
3/22/2022Sell551$23.06$12,706.06View SEC Filing Icon  
3/1/2022Sell56$23.78$1,331.68View SEC Filing Icon  
2/15/2022Sell695$26.57$18,466.15View SEC Filing Icon  
See Full Table

Troy Wichterman Buying and Selling Activity at BioLife Solutions

This chart shows Troy Wichterman's buying and selling at BioLife Solutions by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioLife Solutions Company Overview

BioLife Solutions logo
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Read More

Today's Range

Now: $17.31
Low: $16.41
High: $17.48

50 Day Range

MA: $17.38
Low: $15.14
High: $18.80

2 Week Range

Now: $17.31
Low: $8.92
High: $24.50

Volume

238,929 shs

Average Volume

408,919 shs

Market Capitalization

$784.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67